The Effects of Ketamine on Neuroplasticity in the Brain

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Part of Celia's research focuses on ketamine and alcohol addiction. You're about to start a phase three clinical trial across 10 NHS hospitals, typically the last step before treatment is licensed. The trials will look at using ketamine together with cognitive behavioral therapy or CBT.

Psychedelic drugs have long been been used for their mind-altering effects. Now, they are making their way into western medicine as a treatment for mental health disorders. From July, psychiatrists in Australia will be able to prescribe MDMA for post-traumatic stress disorder, making it the first country in the world to recognise psychedelics as medicines. The US could soon follow, with plans for the US Food and Drug Administration to be asked for approval to treat PTSD with MDMA this year. Ian Sample speaks to correspondent Hannah Devlin about how the science behind psychedelic therapy has progressed, and hears from Prof Celia Morgan about what treatment is actually like, what we know about the risks and what’s left to learn. Help support our independent journalism at theguardian.com/sciencepod